NCT03912818 - Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 10, 2019

Primary Completion Date

August 11, 2022

Study Completion Date

August 11, 2022

Conditions

Bladder AdenocarcinomaBladder Mixed AdenocarcinomaBladder Squamous Cell CarcinomaBladder Urothelial CarcinomaInfiltrating Bladder Urothelial Carcinoma Sarcomatoid VariantInfiltrating Bladder Urothelial Carcinoma With Giant CellsInfiltrating Bladder Urothelial Carcinoma With Glandular DifferentiationInfiltrating Bladder Urothelial Carcinoma With Trophoblastic DifferentiationInfiltrating Bladder Urothelial Carcinoma, Clear Cell VariantInfiltrating Bladder Urothelial Carcinoma, Micropapillary VariantInfiltrating Bladder Urothelial Carcinoma, Nested VariantInfiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant

Interventions

DRUG

Carboplatin

Given IV

DRUG

Cisplatin

Given IV

PROCEDURE

Cystectomy

Undergo cystectomy

DRUG

Doxorubicin

Given IV

BIOLOGICAL

Durvalumab

Given IV

DRUG

Gemcitabine

Given IV

DRUG

Methotrexate

Given IV

DRUG

Vinblastine

Given IV

Trial Locations (1)

94304

Stanford Cancer Institute Palo Alto, Palo Alto